Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Myrna Alexander

Cardiovascular Disease Jackson, MS Medical Doctor

NPI 1285648063 CMS profile 13245

2500 North State Street, Jackson, MS 39216

Open in the dashboard

General payments

$4,618

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Myrna Alexander of Jackson, MS is reported in the CMS Open Payments database as having received $4,618 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $171 2
2024 General $127 2
2023 General $848 26
2022 General $957 44
2021 General $608 32
2020 General $329 20
2019 General $1,577 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Myrna Alexander
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Myrna Alexander were reported at $171. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Myrna Alexander Cardiovascular Disease median Middle half National median
2019 $1,577 $450 $127–$1,392 $163
2020 $329 $242 $77–$751 $114
2021 $608 $335 $101–$1,037 $132
2022 $957 $395 $121–$1,211 $149
2023 $848 $443 $136–$1,283 $160
2024 $127 $450 $136–$1,323 $164
2025 $171 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $840 44 payments
  2. Abiomed $496 12 payments
  3. Novartis Pharmaceuticals Corporation $441 27 payments
  4. Amgen Inc. $374 20 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $317 11 payments
  6. CVRx, Inc. $261 2 payments
  7. E.R. Squibb & Sons, L.L.C. $211 16 payments
  8. AstraZeneca Pharmaceuticals LP $202 8 payments
  9. Boston Scientific Corporation $151 2 payments
  10. Janssen Pharmaceuticals, Inc $150 10 payments
  11. Other $1,175 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,604 200 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS $587 33 payments
  2. Impella $496 12 payments
  3. Repatha $374 20 payments
  4. ENTRESTO $329 22 payments
  5. JARDIANCE $317 11 payments
  6. Barostim Neo System $261 2 payments
  7. VYNDAQEL $244 17 payments
  8. WATCHMAN Access System $151 2 payments
  9. XARELTO $150 10 payments
  10. DEFINITY $143 3 payments
  11. Other $1,852 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

988

Median for Internal Medicine: 777

Drug cost

$131,681

Median for Internal Medicine: $73,373

Branded share of claims

26.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 46 $42,332
Jardiance Empagliflozin Brand 36 $39,169
Eliquis Apixaban Brand 30 $25,898
Farxiga Dapagliflozin Propanediol Brand 15 $11,733
Metoprolol Succinate Generic 105 $1,353
Isosorbide Dinitrate Generic 15 $1,291
Carvedilol Generic 93 $924
Valsartan Generic 17 $863
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 17 $841
Rosuvastatin Calcium Generic 56 $825

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record